- Home
- ATLCP vs HUMAW Comparison
ATLCP vs HUMAW Comparison
Compare ATLCP & HUMAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATLCP
- HUMAW
- Stock Information
- Founded
- ATLCP N/A
- HUMAW 2004
- Country
- ATLCP United States
- HUMAW United States
- Employees
- ATLCP 417
- HUMAW 220
- Industry
- ATLCP Finance: Consumer Services
- HUMAW Biotechnology: Pharmaceutical Preparations
- Sector
- ATLCP Finance
- HUMAW Health Care
- Exchange
- ATLCP Nasdaq
- HUMAW Nasdaq
- Market Cap
- ATLCP N/A
- HUMAW N/A
- IPO Year
- ATLCP N/A
- HUMAW N/A
- Fundamental
- Price
- ATLCP $24.03
- HUMAW $0.20
- Analyst Decision
- ATLCP
- HUMAW
- Analyst Count
- ATLCP 0
- HUMAW 0
- Target Price
- ATLCP N/A
- HUMAW N/A
- AVG Volume (30 Days)
- ATLCP N/A
- HUMAW 14.2K
- Earning Date
- ATLCP N/A
- HUMAW 03-21-2025
- Dividend Yield
- ATLCP N/A
- HUMAW N/A
- EPS Growth
- ATLCP N/A
- HUMAW N/A
- EPS
- ATLCP N/A
- HUMAW N/A
- Revenue
- ATLCP N/A
- HUMAW N/A
- Revenue This Year
- ATLCP N/A
- HUMAW N/A
- Revenue Next Year
- ATLCP N/A
- HUMAW N/A
- P/E Ratio
- ATLCP N/A
- HUMAW N/A
- Revenue Growth
- ATLCP N/A
- HUMAW N/A
- 52 Week Low
- ATLCP N/A
- HUMAW $1.18
- 52 Week High
- ATLCP N/A
- HUMAW $1.34
- Technical
- Relative Strength Index (RSI)
- ATLCP 49.72
- HUMAW 37.94
- Support Level
- ATLCP $23.81
- HUMAW $0.20
- Resistance Level
- ATLCP $24.01
- HUMAW $0.26
- Average True Range (ATR)
- ATLCP 0.34
- HUMAW 0.03
- MACD
- ATLCP -0.03
- HUMAW -0.01
- Stochastic Oscillator
- ATLCP 61.58
- HUMAW 16.25
About ATLCP Atlanticus Holdings Corporation 7.625% Series B Cumulative Perpetual Preferred Stock no par value per share
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.
About HUMAW Humacyte Inc. Warrant
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.